Reduced Vessel Density of the Choriocapillaris during Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration

被引:30
|
作者
Hikichi, Taiichi [1 ]
Agarie, Mitsuko [2 ]
机构
[1] Hikichi Eye Clin, Sapporo, Hokkaido, Japan
[2] Carl Zeiss Meditec Co Ltd, Tokyo, Japan
关键词
anti-VEGF; choriocapillaris; neovascular age-related macular degeneration; optical coherence tomography angiography; vessel density; COHERENCE TOMOGRAPHY ANGIOGRAPHY; POLYPOIDAL CHOROIDAL VASCULOPATHY; VERTEPORFIN PHOTODYNAMIC THERAPY; RETINAL-PIGMENT EPITHELIUM; FOVEAL AVASCULAR ZONE; ANTI-VEGF TREATMENT; QUANTITATIVE-ANALYSIS; VASCULAR DENSITY; RANIBIZUMAB; ATROPHY;
D O I
10.1167/iovs.18-24522
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE. To investigate macular vascular alterations by using optical coherence tomography angiography (OCTA) in patients with a history of long-term anti-vascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration (nAMD). METHODS. Japanese patients with nAMD with a history of long-term anti-VEGF monotherapy at study entry were studied retrospectively. OCTA images were obtained, and the vessel densities (mm(-1)) of the superficial capillary plexus, deep capillary plexus (DCP), choriocapillaris (CC), and the plexus foveal avascular zone area (mm(2)) were calculated. RESULTS. One hundred twenty-four eyes (124 patients) were included. The mean +/- standard deviation follow-up period between the first and last OCTA imaging sessions was 14.5 +/- 3.1 months; the duration of the anti-VEGF monotherapy before the first OCTA imaging session was 68.0 +/- 23.6 months, with a mean of 3.6 +/- 3.0 injections during the follow-up period. The vessel densities of the DCP and CC significantly decreased (P = 0.001 and P = 0.009, respectively) from 10.62 +/- 2.72 mm(-1) and 11.84 +/- 1.79 mm(-1) to 9.44 +/- 2.88 mm(-1) and 11.18 +/- 2.12 mm(-1). Such findings were not observed in 63 control eyes. CONCLUSIONS. The DCP and CC deteriorate during treatment. This information may guide future treatment strategies for nAMD, such as the need to protect the capillaries to maintain visual acuity after long-term treatment. Prospective, controlled trials are required to confirm our findings.
引用
收藏
页码:1088 / 1095
页数:8
相关论文
共 50 条
  • [21] Switching Anti Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration
    Schachat, Andrew P.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2013, 156 (01) : 1 - 2
  • [22] Development of Intraretinal Fluid in Neovascular Age-Related Macular Degeneration During Anti-Vascular Endothelial Growth Factor Treatment
    Cho, Han Joo
    Yoon, Wontae
    Yoon, Jihyun
    Na, Seung Kwan
    Lee, Jihyun
    Kim, Jaemin
    Kim, Chul Gu
    Kim, Jong Woo
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2022, 234 : 6 - 14
  • [23] Efficacy and Safety of Anti-Vascular Endothelial Growth Factor Monotherapies for Neovascular Age-Related Macular Degeneration: A Mixed Treatment Comparison
    Zhang, Yun
    Gao, Sheng
    Li, Xun
    Huang, Xi
    Zhang, Yi
    Chang, Tiancong
    Cai, Zhaolun
    Zhang, Meixia
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [24] Short-term effects of anti-vascular endothelial growth factor on peripapillary choroid and choriocapillaris in eyes with neovascular age-related macular degeneration
    Lee, Boram
    Yoo, Gyeongmin
    Yun, Cheolmin
    Oh, Jaeryung
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2019, 257 (10) : 2163 - 2172
  • [25] Short-term effects of anti-vascular endothelial growth factor on peripapillary choroid and choriocapillaris in eyes with neovascular age-related macular degeneration
    Boram Lee
    Gyeongmin Yoo
    Cheolmin Yun
    Jaeryung Oh
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2019, 257 : 2163 - 2172
  • [26] Patterns of treatment discontinuation in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration
    Dhingra, Narendra
    Upasani, Deepa
    Ghanchi, Faruque
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2022, 70 (06) : 2065 - 2070
  • [27] LONG-TERM REMISSION OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH AS-NEEDED ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY
    Muftuoglu, Ilkay Kilic
    Alam, Mostafa
    You, Qi Sheng
    Gaber, Raouf
    Ramkumar, Hema L.
    Mendoza, Nadia
    Meshi, Amit
    Freeman, William R.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2018, 38 (03): : 516 - 522
  • [28] Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy
    Mones, Jordi
    Biarnes, Marc
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2020, 30 (05) : 1082 - 1090
  • [29] Ten-year outcome of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration
    Upasani, Deepa
    Dhingra, Narendra
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2021, 69 (09) : 2350 - 2354
  • [30] Switching Anti-Vascular Endothelial Growth Factors in Refractory Neovascular Age-Related Macular Degeneration
    Ashraf, Mohammed
    Banaee, Touka
    Silva, Fabiana Q.
    Singh, Rishi P.
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2018, 49 (03) : 166 - +